Oncolytics kicks off reovirus trial

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Natasha Bahri, MD, MS;Daneng Li, MD

Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

ONCOLOGY Staff

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

An unusual patient case was presented during a Frontline Forum where experts worked through how to appropriately treat a patient who was having consistent fevers and pain.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Rachel A. Greenup, MD, MPH

December 23rd 2024

Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer

A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.

Nivolumab/Ipilimumab Combo Elicits Further PFS Benefit in Frontline MSI-H/dMMR mCRC

Broader margins used in lumpectomies can lead to a reduced radiation target area in patients with breast cancer, according to results from a study presented at the 2024 SABCS.

Related Content

Roman Fabbricatore

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Natasha Bahri, MD, MS;Daneng Li, MD

Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

ONCOLOGY Staff

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

An unusual patient case was presented during a Frontline Forum where experts worked through how to appropriately treat a patient who was having consistent fevers and pain.

Rachel A. Greenup, MD, MPH

December 23rd 2024

Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer

A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.